What are the aims of GW Pharmaceuticals?
GW is a pharmaceutical company developing a portfolio of cannabinoid prescription medications to meet patient needs in a wide variety of indications around the world. In April 2005 Sativex® received regulatory approval from Health Canada for use as adjunctive therapy for the symptomatic relief of neuropathic pain in adults with multiple sclerosis. In August 2007, Health Canada approved Sativex® as adjunctive analgesic treatment in patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. Both approvals were secured under the Notice of Compliance with Conditions (NOC/c) policy. Sativex® is marketed in Canada exclusively by Bayer Healthcare. GW’s clinical research is initially focused on Multiple Sclerosis, cancer pain and neuropathic pain. The Company plans to continue to extend its research programme into new areas. In July 2007, GW and Otsuka Pharmaceutical Co., Ltd. announced that th
